Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials

Published:2012-06-24 Issue:2 Volume:69 Page:151-159
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Xiao Yong-Ying,Zhan Ping,Yuan Dong-Mei,Liu Hong-Bing,Lv Tang-Feng,Song Yong,Shi Yi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00228-012-1333-3.pdf

Reference31 articles.

1. Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300

2. Alberg A, Ford J, Samet J (2007) Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines. Chest 132:29S–55S

3. Stinchcombe TE, Socinski MA (2009) Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 6:233–241

4. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–2103

5. Fossella FV, De Vore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354–2362

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequency of Depression and Anxiety in Patients With Lung Cancer Undergoing Chemotherapy: A Single-Center, Cross-Sectional Study From Vietnam;Cureus;2024-09-04

2. Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analysis;Frontiers in Oncology;2024-01-23

3. Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy;BMC Cancer;2023-01-21

4. Trends in Phase II Trials for Cancer Therapies;Cancers;2021-01-07

5. Trends in Phase II trials for cancer therapies;2020-12-09